A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer

Overview of attention for article published in International Journal of Nanomedicine, January 2016

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 59 followers.

A combination of sorafenib and nilotinib reduces the growth of CRPC https://t.co/iK7KPTbxT1

A combination of sorafenib and nilotinib reduces the growth of CRPC https://t.co/0CHGOaTQM4

A combination of sorafenib and nilotinib reduces the growth of CRPC https://t.co/6EiVTi42yN